The Chinese government has decided that the installed capacity of nuclear power plants(NPP)will reach 40 GW by the year of 2020,while other 18 GW under construction,and the electricity produced by NPPs will make up 4%...The Chinese government has decided that the installed capacity of nuclear power plants(NPP)will reach 40 GW by the year of 2020,while other 18 GW under construction,and the electricity produced by NPPs will make up 4%of the whole installed capacity. In such case,the spent fuel generated from those NPPs will reach 82630 tons by 2050.The Chinese policy is that,the spent fuel from light water reactors will be reprocessed first,followed by verification and展开更多
Liaoning Dalmond Group （shorten for Dalmond）, established in 2001, is located on Yingkou City with abundant magnesia resource. Through several years struggle, Dalmond develops to an enterprise group holding several ...Liaoning Dalmond Group （shorten for Dalmond）, established in 2001, is located on Yingkou City with abundant magnesia resource. Through several years struggle, Dalmond develops to an enterprise group holding several company branches.展开更多
Over the past two decades,China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals,keeping in line with the rapidly growing scientific innovat...Over the past two decades,China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals,keeping in line with the rapidly growing scientific innovation in drug research and development(R&D).In this study,we outlined the revolution of drug regulation in China since the establishment of the State Drug Administration in 1998.More particularly,we performed a comprehensive analysis of newly approved anticancer drugs in China from the year 2005 to May 2021,as a powerful illustration of how the revolution has changed the drug R&D landscape.Innovative drug development in China has boomed,benefiting in particular from pro-innovation policies as well as expedited program designations by the authority.We found a significant increase in the number of both imported and domestic new anticancer drugs from 2005 to 2021,with the emergence of drugs with novel mechanisms of action,including immune checkpoint inhibitors and cell therapy products.Drug lag has also been dramatically shortened by more than 70%for imported drugs in years 2016-2020 compared to years 2006-2010.Furthermore,we provide an insight into the potential approaches to further optimize the science-based and clinical value-based regulatory and R&D drug ecosystem in China.This review provides evidence of significant impacts of regulations and policies on drug R&D and suggests that the constantly adapting regulatory ecosystem will speed up drug development in China and worldwide.展开更多
With the support by the National Key R&D Program of China,the National Natural Science Foundation of China,and the Chinese Academy of Sciences,the research team led by Prof.Wang JiangYun (王江云) at the Institute ...With the support by the National Key R&D Program of China,the National Natural Science Foundation of China,and the Chinese Academy of Sciences,the research team led by Prof.Wang JiangYun (王江云) at the Institute of Biophysics,CAS,rationally designed a genetically encoded photosensitizer protein (PSP)that facilitates photocatalytic CO2 reduction,which was published in Nature Chemistry (2018, DOI :10.1038/s41557-018-0150-4).展开更多
文摘The Chinese government has decided that the installed capacity of nuclear power plants(NPP)will reach 40 GW by the year of 2020,while other 18 GW under construction,and the electricity produced by NPPs will make up 4%of the whole installed capacity. In such case,the spent fuel generated from those NPPs will reach 82630 tons by 2050.The Chinese policy is that,the spent fuel from light water reactors will be reprocessed first,followed by verification and
文摘Liaoning Dalmond Group （shorten for Dalmond）, established in 2001, is located on Yingkou City with abundant magnesia resource. Through several years struggle, Dalmond develops to an enterprise group holding several company branches.
文摘Over the past two decades,China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals,keeping in line with the rapidly growing scientific innovation in drug research and development(R&D).In this study,we outlined the revolution of drug regulation in China since the establishment of the State Drug Administration in 1998.More particularly,we performed a comprehensive analysis of newly approved anticancer drugs in China from the year 2005 to May 2021,as a powerful illustration of how the revolution has changed the drug R&D landscape.Innovative drug development in China has boomed,benefiting in particular from pro-innovation policies as well as expedited program designations by the authority.We found a significant increase in the number of both imported and domestic new anticancer drugs from 2005 to 2021,with the emergence of drugs with novel mechanisms of action,including immune checkpoint inhibitors and cell therapy products.Drug lag has also been dramatically shortened by more than 70%for imported drugs in years 2016-2020 compared to years 2006-2010.Furthermore,we provide an insight into the potential approaches to further optimize the science-based and clinical value-based regulatory and R&D drug ecosystem in China.This review provides evidence of significant impacts of regulations and policies on drug R&D and suggests that the constantly adapting regulatory ecosystem will speed up drug development in China and worldwide.
文摘With the support by the National Key R&D Program of China,the National Natural Science Foundation of China,and the Chinese Academy of Sciences,the research team led by Prof.Wang JiangYun (王江云) at the Institute of Biophysics,CAS,rationally designed a genetically encoded photosensitizer protein (PSP)that facilitates photocatalytic CO2 reduction,which was published in Nature Chemistry (2018, DOI :10.1038/s41557-018-0150-4).
